Grigorios Siokas Buys 61,614 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 61,614 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average price of $0.65 per share, with a total value of $40,049.10. Following the completion of the transaction, the chief executive officer owned 6,220,498 shares of the company’s stock, valued at approximately $4,043,323.70. The trade was a 1.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cosmos Health Trading Up 2.6%

Shares of NASDAQ COSM traded up $0.02 during mid-day trading on Thursday, reaching $0.67. The company had a trading volume of 279,701 shares, compared to its average volume of 614,141. The business’s 50-day moving average is $0.94 and its 200-day moving average is $0.71. The company has a current ratio of 0.99, a quick ratio of 0.82 and a debt-to-equity ratio of 0.25. The stock has a market cap of $23.26 million, a price-to-earnings ratio of -0.88 and a beta of 5.32. Cosmos Health Inc. has a 52 week low of $0.28 and a 52 week high of $1.32.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The company had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. Equities analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on COSM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, October 8th. Wall Street Zen upgraded Cosmos Health to a “hold” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cosmos Health

An institutional investor recently raised its position in Cosmos Health stock. Armistice Capital LLC increased its holdings in Cosmos Health Inc. (NASDAQ:COSM) by 156.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,917,710 shares of the company’s stock after buying an additional 1,168,884 shares during the period. Armistice Capital LLC owned about 7.03% of Cosmos Health worth $836,000 as of its most recent filing with the Securities & Exchange Commission. 12.61% of the stock is currently owned by institutional investors.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.